Iovance Biotherapeutics Posts Q3 Loss of $0.05 a Share
Iovance reported a Q3 loss of $0.05 per share, versus the FactSet estimate of a $0.08 loss.
Related stories
Iovance Biotherapeutics reports Q3 revenue of $121.5 million
Iovance reported Q3 revenue of $121.5 million, versus a FactSet estimate of $116.0 million.
M impact | EQUITY | Nov 05, 2026, 12:33 PM UTC
LSI Industries Reports Fiscal Q1 Revenue of $225.9M
Fiscal Q1 revenue was $225.9 million, versus the FactSet estimate of $225.0 million.
M impact | EQUITY | Nov 05, 2026, 12:27 PM UTC
Wendy’s Reports Q3 Revenue of $547.0M
Wendy’s reported third-quarter revenue of $547.0 million, versus a FactSet estimate of $531.3 million.
M impact | EQUITY | Nov 05, 2026, 12:26 PM UTC
Bikaji Foods Q2 Profit Falls 11.3% Despite 13.1% Revenue Growth
Bikaji Foods reported second-quarter FY27 net profit of ₹70.78 crore, down from ₹79.77 crore a year earlier, while revenue rose 13.1%. Higher expenses contributed to the profit dec
M impact | EQUITY | Nov 05, 2026, 12:26 PM UTC
Innovo Construction Wins $132 Million Marassi Red Contract
Innovo Construction signed a 7.1 billion Egyptian-pound ($132 million) contract with Emaar Misr for the first phase of the Marassi Red project on Egypt’s Red Sea coast. The 27-mont
M impact | EQUITY | Nov 05, 2026, 12:26 PM UTC
Dream Finders Homes Reports More Than 98% Early Tenders in Beazer Note Exchange
Dream Finders Homes said early tenders exceeded 98% of each Beazer note series in its private exchange offer.
L impact | EQUITY | Nov 05, 2026, 12:26 PM UTC